Mark Fasulo, MD
Cardiovascular Disease · Beaumont, TXNPI 1366686487
Payments from drug & device makers
Across 411 payments — averaging $971.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$259K
- Boehringer Ingelheim$73K
- Johnson & Johnson$30K
- AstraZeneca$29K
- Abbott$4K
- Edwards Lifesciences$1K
- plus $4K from 23 others
Across 4 payments — averaging $4277.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$17K
What the payments were for
- Consulting fees$3001%
- Speaking & faculty fees$31,00073%
- Travel & lodging$3,8839%
- Food & beverage$7,36317%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 7 | $259,135 |
| Boehringer Ingelheim | 9 | $72,559 |
| Johnson & Johnson | 43 | $30,466 |
| AstraZeneca | 11 | $28,611 |
| Abbott | 53 | $3,825 |
| Edwards Lifesciences | 89 | $1,314 |
| Boston Scientific | 47 | $808 |
| Medtronic(2 entities) | 34 | $586 |
| Merck | 17 | $296 |
| Actelion Pharmaceuticals US, Inc. | 12 | $220 |
| Pfizer | 15 | $204 |
| E.r. Squibb & Sons, L.L.C. | 14 | $194 |
| Amgen | 14 | $166 |
| Inspire Medical Systems, Inc. | 4 | $142 |
| Novartis | 7 | $131 |
| Mallinckrodt Hospital Products Inc. | 1 | $128 |
| Lexicon Pharmaceuticals, Inc. | 4 | $124 |
| Esperion Therapeutics, Inc. | 3 | $121 |
| Cardiovascular Systems Inc. | 4 | $103 |
| Irhythm Technologies, Inc. | 5 | $81 |
| Sanofi-aventis U.S. LLC | 4 | $69 |
| Biotronik Inc. | 2 | $44 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $33 |
| Tactile Systems Technology Inc | 2 | $29 |
| Innovation Technologies Inc | 1 | $28 |
| Shockwave Medical, Inc | 1 | $21 |
| BD | 1 | $20 |
| Chiesi USA, Inc. | 1 | $13 |
| Heartflow, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$29,963
- FARXIGA$3,367
- AVEIR$1,212
- Xience V coronary stent system$987
- Assurity Pacemaker$222
- Mitra Clip system$186
- Allure CRT Pacemaker$174
- Endurity Pacemaker$154
- ACTHAR$128
- NEXLIZET$103
- NEXLETOL$103
How this compares
$399,480 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 674 | $644,138 |
| XareltoRivaroxaban | 416 | $401,628 |
| EntrestoSacubitril/Valsartan | 157 | $137,635 |
| Repatha SureclickEvolocumab | 119 | $85,986 |
| MultaqDronedarone Hcl | 23 | $34,429 |
| BrilintaTicagrelor | 39 | $30,162 |
| Repatha PushtronexEvolocumab | 45 | $28,261 |
| FarxigaDapagliflozin Propanediol | 23 | $17,446 |
| Praluent PenAlirocumab | 18 | $14,241 |
| Metoprolol Succinate | 771 | $13,234 |
| Valsartan | 216 | $8,908 |
| Prasugrel Hcl | 208 | $8,827 |
| Ranolazine ErRanolazine | 117 | $8,826 |
| NexletolBempedoic Acid | 19 | $8,361 |
| ClopidogrelClopidogrel Bisulfate | 572 | $6,600 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $204 | $644,138674 claims |
| Johnson & JohnsonXarelto | $30,466 | $401,628416 claims |
| NovartisEntresto | $131 | $137,635157 claims |
| AstraZenecaBrilinta, Farxiga | $28,611 | $47,60862 claims |
| Sanofi-aventis U.S. LLCMultaq | $69 | $34,42923 claims |
| Esperion Therapeutics, Inc.Nexletol | $121 | $8,36119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Beaumont
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
- Fernando BoccalandroOdessa$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.